Testicular cancer trial: could a stronger chemo course cut relapse risk?
NCT ID NCT02341989
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This phase 3 trial tests whether one course of BEP chemotherapy works better than one course of carboplatin to prevent seminoma testicular cancer from coming back after surgery. It includes 348 men with stage I seminoma who have risk factors like a large tumor or rete testis invasion. The study compares relapse rates and side effects between the two treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEMINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institutt for kreftforskning og molekylær medisin, St Olavs Hospital
Trondheim, Norway
-
St. Olavs University hospital HF
Trondheim, Norway
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bleomycin, etoposide, and cisplatin (BEP) or carboplatin
What this could lead to
If BEP works better, it could offer a more effective single-course option to prevent seminoma from coming back after surgery.
What could go wrong
This is an early-phase comparison; BEP may cause more side effects than carboplatin, and the trial is not yet complete. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.